NSRX

Nasus Pharma Ltd. (NSRX) SWOT Analysis Analysis (2026)

Invetso Score: 2.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.8 (Weak)

Liquidity is unusually strong versus peers, with current and quick ratios near 8.8, which materially reduces near-term funding pressure despite weak profitability.

Leverage appears low on a debt-to-equity basis, so balance-sheet fragility is less severe than for more levered peers even though net debt remains meaningful.

Cash conversion cycle is reported at zero, indicating working-capital efficiency that can support operating flexibility relative to peers with longer cash cycles.

Weaknesses

Score:

Return on invested capital is deeply negative at -96.5%, showing capital is being deployed far less efficiently than profitable peers and undermining long-term value creation.

The absence of reported operating and gross margins limits evidence of durable unit economics, while peers with positive margins typically show clearer structural resilience.

Net debt to EBITDA above 1.0x is manageable but still constrains flexibility versus stronger peers with net cash or lower leverage.

Opportunities

Score:

If management converts excess liquidity into higher-return assets, the company could narrow the profitability gap versus peers that already earn acceptable returns on capital.

A low debt-to-equity profile leaves room for balance-sheet optimization, which could improve competitive positioning if deployed into accretive growth rather than maintenance spending.

Working-capital discipline can preserve cash for reinvestment, giving the company more optionality than peers with slower cash conversion and tighter liquidity.

Threats

Score:

Persistently negative returns on capital increase the risk that peers with positive ROIC will compound market share and valuation advantages over time.

If liquidity is used to fund losses rather than growth, the current balance-sheet cushion can erode faster than for peers with self-funding operations.

Without visible margin strength, the company remains exposed to competitive pricing pressure from peers with stronger cost structures and better operating leverage.

Overall Score

Score:

NSRX shows a weak structural position versus peers because exceptional liquidity is outweighed by deeply negative capital returns and limited evidence of durable profitability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Nasus Pharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →